Spontaneous mutation frequencies and spectra in p53 (+/+) and p53 (-/-) mice: A test of the 'guardian of the genome' hypothesis in the Big Blue® transgenic mouse mutation detection system

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 379, Issue 1, 1997, Pages 13-20

  Buettner, Victoria L ^a   Nishino, Hiroshi ^a   Haavik, Jan ^a   Knöll, Antje ^a   Hill, Kathleen ^a   Sommer, Steve S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Big Blue mouse; lacI; Somatic mutation

Indexed keywords

PROTEIN P53;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; GENE SEQUENCE; GENOME; LIVER; MOUSE; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; SOMATIC MUTATION; SPLEEN; SPONTANEOUS MUTATION; TRANSGENIC MOUSE;

ANIMALS; BACTERIAL PROTEINS; DNA MUTATIONAL ANALYSIS; ESCHERICHIA COLI PROTEINS; GENE FREQUENCY; GENES, P53; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; ORGAN SPECIFICITY; REPRESSOR PROTEINS;

ANIMALIA; MUS MUSCULUS;

EID: 0030855899     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00078-X     Document Type: Article

References (35)

1. Cross S.M., Sanchez C.A., Morgan C.A., Schimke M.K., Ramel S., Idzerda R.L., Raskind W.H., Reid B.J. A p53-dependent mouse spindle checkpoint. Science. 267:1995;1353-1356.
2. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
3. Ford M.J., Hanawalt P.C. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc. Natl. Acad. Sci USA. 92:1995;8876-8880.
4. Guillouf C., Rosselli F., Krishnaraju K., Moustacchi E., Hoffman B., Liebermann D.A. p53 involvement in control of G2 exit of the cell cycle: Role in DNA damage-induced apoptosis. Oncogene. 10:1995;2263-2270.
5. ® transgenic mouse mutation detection system. BioTechniques. 20:1996;988-994.
6. Harvey M., Vogel H., Morris D., Bradley A., Bernstein A., Donehower L.A. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genet. 9:1995;305-311.
7. Havre P.A., Yuan J., Hedrick L., Cho K.R., Glazer P.M. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res. 55:1995;4420-4424.
8. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancer. Science. 253:1992;49-53.
9. Jayaraman L., Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell. 81:1995;1021-1029.
10. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
11. Kawashima K., Mihara K., Usuki H., Shimizu N., Namba M. Transfected mutant p53 gene increases X-ray-induced cell killing and mutation in human fibroblasts immortalized with 4-nitroquinoline 1-oxide but does not induce neoplastic transformation of the cells. Int. J. Cancer. 61:1995;76-79.
12. Knöll A., Jacobson D.P., Kretz P.L., Lundberg K.S., Short J.M., Sommer S.S. Spontaneous mutations in lacI-containing lambda lysogens derived from transgenic mice: The observed patterns differ in liver and spleen. Mutation Res. 311:1994;57-67.
13. Kohler S.W., Provost G.S., Fieck A., Kretz P.L., Bullock W.O., Sorge J.A., Putman D.L., Short J.M. Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice. Proc. Natl. Acad. Sci. USA. 88:1991;7958-7962.
14. Kuerbitz S.J., Plunkett B.S., Walsh W.V., Kastan M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:1992;7491-7495.
15. Lane D.P. p53, guardian of the genome. Nature. 358:1992;15-16.
16. Lee S., Elenbaas B., Levine A., Griffith J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell. 81:1995;1013-1020.
17. Li F.P., Fraumeni J.F. Jr., Mulvihill J.J., Blattner W.A., Dreyful M.G., Tucker M.A., Miller R.W. A cancer family syndrome in twenty-four kindreds. Cancer Res. 48:1988;5358-5362.
18. Malkin D. p53 and the Li-Fraumeni syndrome. Biochim. Biophys. Acta. 1198:1994;197-213.
19. Mehta C.R., Patel N.R. A network algorithm for performing Fisher's exact test in r×c contingency tables. J. Am. Stat. Assoc. 78:1983;427-434.
20. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weston A., Modali R., Harris C.C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature. 342:1989;705-708.
21. Nishino H., Herath J.F., Jenkins R.B., Sommer S.S. Fluorescence in situ hybridization for rapid differentiation of zygosity in transgenic mice. BioTechniques. 19:1995;587-592.
22. ® transgenic mice have similar frequencies and patterns of observed mutation in liver, spleen and brain. Oncogene. 11:1995;263-270.
23. ® transgenic mice: Analysis of age, gender, and tissue type. Environ. Mol. Mutagen. 28:1996;299-312.
24. ® transgenic mouse mutagenesis assay: The mutational spectrum of ex vivo pinpoint mutant plaques. Mutation Res. 372:1996;97-105.
25. Provost G.S., Kretz P.L., Hamner R.T., Matthews C.D., Rogers B.J., Lundberg K.S., Dycaico M.J., Short J.M. Transgenic systems for in vivo mutation analysis. Mutation Res. 288:1993;133-149.
26. Sands A.T., Suraokar M.B., Sanchez A., Marth J.E., Donehower L.A., Bradley A. p53 deficiency does not affect the accumulation of point mutations in a transgene target. Proc. Natl. Acad. Sci. USA. 92:1995;8517-8521.
27. Skopek T.R. Of mice and mutants: Target size and sensitivity. Mutation Res. 331:1995;225-228.
28. ® B6C3F1 mice. Environ. Mol. Mutagen. 26:1995;9-15.
29. ® B6C3F1 mice. Environ. Mol. Mutagen. 28:1996;376-384.
30. Smith M.L., Chen I., Zhan Q., O'Connor P.M., Fornace A.J. Jr. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene. 10:1995;1053-1059.
31. Sommer S.S., Ketterling R.P. How precisely can data from transgenic mouse mutation-detection systems be extrapolated to humans?: Lessons from the human factor IX gene. Mutation Res. 307:1994;517-531.
32. Stewart N., Hicks G.G., Paraskevas F., Mowat M. Evidence for a second cell cycle block at G2/M by p53. Oncogene. 10:1995;109-115.
33. Stoflet E.S., Koeberl D.D., Sarkar G., Sommer S.S. Genomic amplification with transcript sequencing. Science. 239:1988;491-494.
34. Walker V.E., Gorelick N.J., Andrews J.L., Craft T.R., DeBoer J.G., Glickman B.W., Skopek T.R. Frequency and spectrum of ethylnitrosourea-induced mutation at the hprt and lacI loci in splenic lymphocytes of exposed lacI transgenic mice. Cancer Res. 56:1996;4654-4661.
35. Wang X.W., Yeh H., Schaeffer L., Roy R., Moncollin V., Egly J., Wang Z., Friedberg E.C., Evans M.K., Taffe B.G., Bohr V.A., Weeda G., Hoeijmakers J.H.J., Forrester K., Harris C.C. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet. 10:1995;188-195.